Soulié P - Search Results

1

Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.

Soulié P, Trandafir L, Taamma A, Lokiec F, Brain E, Delord JP, Mita A, Vannetzel JM, Cvitkovic E, Misset JL. Soulié P, et al. Anticancer Drugs. 1997 Sep;8(8):763-6. doi: 10.1097/00001813-199709000-00005. Anticancer Drugs. 1997. PMID: 9396620 Clinical Trial.

2

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

Soulié P, Bensmaïne A, Garrino C, Chollet P, Brain E, Fereres M, Jasmin C, Musset M, Misset JL, Cvitkovic E. Soulié P, et al. Eur J Cancer. 1997 Aug;33(9):1400-6. doi: 10.1016/s0959-8049(97)00122-6. Eur J Cancer. 1997. PMID: 9337681 Clinical Trial.

3

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.

Soulié P, Garrino C, Bensmaïne MA, Bekradda M, Brain E, Di Palma M, Goupil A, Misset JL, Cvitkovic E. Soulié P, et al. J Cancer Res Clin Oncol. 1999 Dec;125(12):707-11. doi: 10.1007/s004320050338. J Cancer Res Clin Oncol. 1999. PMID: 10592105 Clinical Trial.

4

6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.

Brain EC, Mita A, Soulié P, Errihani H, Hardy Bessard AC, Chaouche M, Alexandre J, Delord JP, Cvitkovic E, Jasmin C, Misset JL. Brain EC, et al. Among authors: soulie p. J Cancer Res Clin Oncol. 1997;123(4):227-31. doi: 10.1007/BF01240320. J Cancer Res Clin Oncol. 1997. PMID: 9177496

5

Paclitaxel (Taxol)-associated junctional tachycardia.

Faivre S, Goldwasser F, Soulié P, Misset JL. Faivre S, et al. Among authors: soulie p. Anticancer Drugs. 1997 Aug;8(7):714-6. doi: 10.1097/00001813-199708000-00011. Anticancer Drugs. 1997. PMID: 9311449

6

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.

Mita C, Chatelut E, Bekradda M, Soulié P, Canal P, Misset JL, Cvitkovic E, Bugat R. Mita C, et al. Among authors: soulie p. Ann Oncol. 2003 Dec;14(12):1776-82. doi: 10.1093/annonc/mdg490. Ann Oncol. 2003. PMID: 14630684 Free article. Clinical Trial.

7

[Oxaliplatin: the first DACH platinum in clinical practice].

Soulié P, Raymond E, Brienza S, Cvitkovic E. Soulié P, et al. Bull Cancer. 1997 Jun;84(6):665-73. Bull Cancer. 1997. PMID: 9295871 French.

8

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.

Trandafir L, Ruffié P, Borel C, Monnet I, Soulié P, Adams D, Cvitkovic E, Armand JP. Trandafir L, et al. Among authors: soulie p. Eur J Cancer. 1997 Oct;33(11):1900-2. doi: 10.1016/s0959-8049(97)00263-3. Eur J Cancer. 1997. PMID: 9470855 Clinical Trial.

9

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.

Germann N, Brienza S, Rotarski M, Emile JF, Di Palma M, Musset M, Reynes M, Soulié P, Cvitkovic E, Misset JL. Germann N, et al. Among authors: soulie p. Ann Oncol. 1999 Mar;10(3):351-4. doi: 10.1023/a:1008310708853. Ann Oncol. 1999. PMID: 10355582 Free article. Clinical Trial.

10

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.

Soulié P, Ruffié P, Trandafir L, Monnet I, Tardivon A, Terrier P, Cvitkovic E, Le Chevalier T, Armand JP. Soulié P, et al. J Clin Oncol. 1996 Mar;14(3):878-85. doi: 10.1200/JCO.1996.14.3.878. J Clin Oncol. 1996. PMID: 8622036 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

379 results

Search Page

Filters